Taking peoplePhase 1
NG004 in Incomplete Spinal Cord Injury Patients
Key facts
- Who runs it
- NovaGo Therapeutics AG
- Where
- Germany and Switzerland10 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 120 people, planned
- Started
- 5 Aug 2026
- Expected to end
- Jul 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- NG004
- Placebo
- Record updated
- 23 October 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Acute incomplete cervical SCI (Neurological level of injury C1 ≤ lesion ≤ C8) with confirmed classification of American Spinal Injury Association (ASIA) impairment scale (AIS) B, C and D at Screening
- 4-28 days post-injury and no earlier than 4 days after spinal surgery
- No required mechanical ventilation or patients that do not completely depend on mechanical ventilation
- Hemodynamically and clinical stable patient according to the acute SCI condition at baseline
Who cannot take part
- Patients with uncontrolled bleeding diathesis and/or who require concomitant therapeutic anticoagulation and not related to SCI
- Drug dependence any time within the last 6 months before Screening
- Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations
- Other significant pre-existing or current severe systemic disease
- History of or an episode of multiple sclerosis or Guillain-Barre syndrome
- History of recent meningitis or meningoencephalitis
- History of refractory epilepsy
- Presence of any unstable medical or psychiatric condition
- History of a life-threatening allergic or immune-mediated reaction
- Presence of infection around the location where the spinal needle insertions are planned for applying the intrathecal injections
- Trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds
- Multiple levels of clinically relevant spinal cord lesions
- Major brachial or lumbar plexus damage/trauma
- Significant head trauma or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function
- Pregnant or nursing women
- Patients who are unconscious
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a randomized, double-blind, placebo controlled, multicenter trial of NG004 in patients with acute traumatic incomplete cervical SCI. The trial will evaluate the safety and tolerability, PK, and effects on motor function and daily life functioning of NG004 compared with placebo.
The 2 groups in the trial
- NG004Treatment being tested
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized, Double-blind, Placebo Controlled Clinical Trial to Investigate the Human Monoclonal Antibody NG004 in Acute, Incomplete Cervical Spinal Cord Injury (SCI) Patients
- Fit questions
- Built from NCT07840196, who can take part
- Record updated
- 23 October 2026